2025年1-11月，天津市工业企业数（以下数据涉及的工业企业，均为规模以上工业企业，从2011年起， 规模以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万元）为6286 个，和上年同期相比，增加了105个，同比增长1.7%，占全国的比重为1.2%。 2016-2025年1-11月天津市工业企业数统计图 数据来源：国家统计局，智研咨询整理 上市公司：渤海化学（600800），桂发祥（002820），力生制药（002393），利安隆（300596），津药 药业（600488），久日新材（688199），赛象科技（002337），长荣股份（300195），建科机械 （300823），津荣天宇（300988），中重科技（603135），恒银科技（603106），广宇发展 （000537），金开新能（600821） 相关报告：智研咨询发布的《2026-2032年中国工业云行业市场深度评估及投资机会预测报告》 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的 ...

Core Viewpoint - The article highlights the evolution and modernization of Lisheng Pharmaceutical, emphasizing its commitment to public health and innovation while maintaining its historical roots through the "Three Fish" brand established in 1930 [1][2]. Group 1: Company History and Philosophy - Lisheng Pharmaceutical was founded in 1930 to address the lack of affordable medicine for the public, with the "Three Fish" trademark symbolizing its commitment to making medicine accessible [2]. - The company's philosophy of "for the people" has been a guiding principle, focusing on the integration of raw materials and formulations to ensure affordability and availability of medications [2]. Group 2: Innovation and Product Development - Lisheng has increased its R&D investment, with over 8% of its budget allocated to research in the first half of 2025, resulting in the approval of key products and multiple patent applications [3]. - The company is focusing on high-end generic drugs, modified new drugs for specific populations, and original innovations in critical areas such as synthetic biology and gene therapy [3]. Group 3: Brand Modernization and Marketing Strategy - The "Three Fish" brand has been revitalized to resonate with younger consumers, incorporating cultural narratives and modern marketing strategies such as short online dramas to enhance brand visibility [4][6]. - Lisheng has developed a multi-channel marketing network, utilizing OTC, medical, and online platforms to reach diverse consumer groups effectively [6][7]. - The "Shoubi Mountain" brand is transitioning from a single product to a comprehensive series of antihypertensive medications, with plans to expand its product range significantly [7].

上市公司：海南海药（000566），东北制药（000597），亚太实业（000691），通化金马（000766）， 北大医药（000788），力生制药（002393），海普瑞（002399），科伦药业（002422），杭氧股份 （002430），长江健康（002435），誉衡药业（002437），华软科技（002453） 相关报告：智研咨询发布的《2025-2031年中国基础化学原料行业市场供需态势及投资前景研判报告》 根据国家统计局数据可知：2025年11月全国化学原料和化学制品制造业出口货值为472.1亿元，同比增 长2.3%；2025年1-11月全国化学原料和化学制品制造业累计出口货值为5078.9亿元，累计同比增长 0.5%。 2019年-2025年1-11月全国化学原料和化学制品制造业出口货值统计图 数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 ...

Group 1 - The flu epidemic in China is at a high level, primarily driven by the H3N2 strain, with increased transmission risk due to upcoming population movements during the New Year holiday [1] - Demand for antiviral and symptomatic medications has surged, with a reported over 500% increase in flu-related drug purchases on Alibaba Health and over 100% increase in orders for traditional Chinese medicine on Meituan [1] - The pharmaceutical industry is responding effectively across the supply chain, from vaccine production to drug distribution, indicating a well-coordinated effort to manage the public health challenge [1][2] Group 2 - Vaccine companies are ramping up production, with Hualan Vaccine reporting 55 batches of flu vaccine issued since November, reflecting increased public willingness to get vaccinated [2] - Diagnostic companies like Dian Diagnostics and Kingmed Diagnostics are seeing increased business, supporting the trend of testing before treatment, which enhances rational drug use [2] - The treatment landscape is diversifying, with both chemical and traditional Chinese medicines being utilized, indicating a shift in market dynamics [3][5] Group 3 - Traditional Chinese medicine is gaining traction, with companies like China Resources Sanjiu and Kangyuan Pharmaceutical seeing strong growth in their antiviral product lines [5] - The distribution sector is crucial, with companies like Yiyigou ensuring rapid delivery of essential medications during peak demand periods [5] - The clinical relevance of traditional Chinese medicine is increasing, supported by government policies that endorse its use in flu treatment, leading to a rise in evidence-based research [6][9] Group 4 - Companies are focusing on clinical research to validate the efficacy of traditional Chinese medicines, with Kangyuan Pharmaceutical conducting head-to-head trials against conventional drugs [7][9] - The competitive landscape in the respiratory system traditional Chinese medicine market is diverse, with companies like China Resources Sanjiu and Yiling Pharmaceutical leveraging brand strength and market recognition [9] - As the industry moves towards evidence-based medicine, companies with strong research capabilities and clinical data are likely to capture more market opportunities [9]

Core Viewpoint - On December 30, a total of 7 listed companies will have their restricted shares unlocked, with a total market value of approximately 11.55 billion yuan [1]. Group 1: Company Specifics - Lisheng Pharmaceutical (Stock Code: 002393) will unlock 497,000 shares under equity incentive restrictions [1]. - Xuefeng Technology (Stock Code: 603227) will unlock 97.6172 million shares from the issuance of A-shares to institutional investors [1]. - Su Yan Jingshen (Stock Code: 603299) will unlock 622,700 shares under equity incentive restrictions [1]. - Qianhe Flavoring (Stock Code: 603027) will unlock 2.043 million shares under equity incentive restrictions [1]. - Hongming Co., Ltd. (Stock Code: 301105) will unlock 3.375 million shares from pre-issuance restrictions [1]. - Fulede (Stock Code: 301297) will unlock 200 million shares from pre-issuance restrictions [1]. - Baiwei Storage (Stock Code: 688525) will unlock 11.4 million shares [1].

大家早上壕！ 先看海外要闻： 美股调整加剧，道指收跌0.51%、纳指收跌0.50%、标普500收跌0.35%；特斯拉收跌3.27%、英伟达跌1.21%、Meta、亚马逊、微软至多跌 0.69%，谷歌A、苹果则至多收涨0.13%。 特朗普：正考虑以"严重失职"为由起诉鲍威尔，1月或公布下任美联储主席人选。 Meta数十亿美元收购AI智能体Manus，肖弘将出任Meta副总裁。 软银斥资40亿美元收购数据中心投资公司DigitalBridge，以助力AI业务推进。 美国最大电网"容量拍卖"内幕：若无价格管制，AI热潮本将令电价再涨60%。 英特尔完成向英伟达出售价值50亿美元的普通股。 "我可能早了，但没错！"大空头Burry再次逆市而为，做空AI双雄英伟达和Palantir。 国际贵金属大幅收跌，COMEX黄金期货跌4.45%、COMEX白银期货跌7.2%、现货白银大跌近9%、现货钯金跌超15%、现货铂金跌超14%。 国内重大事件汇总： 今日券商策略前瞻： 光大证券表示，沪指虽然9连阳，但连续两个交易日个股都是多数收跌，场内资金分歧明显；但考虑到4000点已经近在眼前，多头或将推动沪指 继续向4000点震荡上行 ...

Group 1: Fiscal Policy and Economic Measures - The Ministry of Finance has outlined key tasks for 2026, focusing on implementing a more proactive fiscal policy, which includes expanding the fiscal expenditure framework to ensure necessary spending levels [1] - The government aims to optimize the combination of government bond tools to enhance their effectiveness and improve the efficiency of transfer payment funds to increase local financial autonomy [1] - There will be a continuous optimization of expenditure structure to strengthen support for key areas and enhance fiscal-financial collaboration to amplify policy effectiveness [1] Group 2: Consumption and Subsidy Adjustments - The Ministry of Finance plans to significantly boost consumption in the coming year by implementing special actions to support the replacement of consumer goods and adjusting the scope and standards of subsidies [4] Group 3: Infrastructure and Environmental Initiatives - The first "6-lane to 12-lane" highway expansion project in China has been completed, marking a significant upgrade of the Beijing-Taiwan Expressway in Shandong Province [5] - A major carbon capture and storage project in Xinjiang has been established, which is expected to inject over 1 million tons of carbon dioxide annually by 2025, representing a significant step in carbon capture and utilization [6] Group 4: Corporate Developments - Ningde Times announced plans to scale up the application of sodium batteries across various sectors, including battery swapping, passenger vehicles, commercial vehicles, and energy storage in 2026, indicating a trend towards dual battery technologies [16] - Kweichow Moutai's chairman emphasized the importance of preventing price speculation and ensuring reasonable pricing to maintain market stability and consumer trust [15] Group 5: Market Trends and Stock Performance - The A-share market has seen a significant increase in the number of doubling stocks, with 528 stocks achieving this status in 2025, driven primarily by AI and merger and acquisition themes [17] - This week, the market experienced a decrease in the scale of restricted stock listings, with a total of approximately 580.97 billion yuan in market value being released [18]

大家早上壕！ 先看海外要闻： 美股迎小幅调整，道指收跌0.04%、纳指收跌0.09%、标普500收跌0.03%；英伟达收涨1.02%、亚马逊收涨0.06%、特斯拉收跌2.10%、Meta、谷 歌A、苹果、微软至多跌0.64%。 全球多地的数据中心开发商正采用航空发动机衍生的涡轮机和化石燃料发电机进行发电。 白银期货涨超10%，创历史新高逼近80美元关口；现货铂金涨8.84%，刷新历史高位；现货钯金涨12.38%；纽约铜涨5%；周一亚市早盘白银再度 大涨逾5%。 芝商所12月26日发布重大保证金调整通知称，将于12月29日收盘后，全面上调黄金、白银、锂等金属期货品种的履约保证金。 全球最大的黄金ETF SPDR Gold Trust持仓量为1071.13吨，较前一个交易日增加2.86吨。全球最大的白银ETF iShares Silver Trust持仓量为16390.56 吨，较前一个交易日减少56.41吨。 特朗普称俄乌"接近达成协议"，"20点和平计划"已95%谈妥。 国内重大事件汇总： 一周券商策略前瞻： 本周各家券商策略分析师整体依旧保持乐观。 华西策略李立峰团队称，岁末年初多头势力聚集，"春季躁动"行 ...

证券代码：002393 证券简称：力生制药 公告编号：2025-089 天津力生制药股份有限公司 重要提示： 1.本次解除2022年限制性股票激励计划首次授予部分第二次解除限售的股票数量为 583,044股，占公司总股本0.2263%，涉及股东人数66人； 2.本次解除限售的股份上市流通日期为：2025年12月30日。 天津力生制药股份有限公司（以下简称"公司"或"本公司"）于2025年12月05日召开第八 届董事会第二次会议审议通过了《关于2022年限制性股票激励计划首次授予部分第二个解 除限售期解除限售条件成就的议案》。公司董事会认为公司2022年限制性股票激励计划首 次授予部分的第二个解除限售期已符合解除限售条件。 根据公司2022年第五次临时股东大会审议授权及公司2022年限制性股票激励计划相关 规定，公司办理了2022年限制性股票激励计划首次授予部分第二次解除限售并上市流通手 续，现就有关事项说明如下： 一、公司股权激励计划简述及实施情况 关于 2022 年限制性股票激励计划首次授予部分 第二次解除限售并上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 ...

Group 1 - The company announced an investment of 85 million yuan in a structured deposit with a floating return from Industrial Bank's Tianjin branch, with an expected annual yield of 1.20%-1.60% [2] - As of the announcement date, the company has a cash management balance of 155 million yuan, which is below the authorized limit of 600 million yuan [2]